FARN:LON
Faron Pharmaceuticals Oy
36,60 GBX
arrow_upward
+0,27%(+0,100) 1 d.
12. okt., 16:30:00 GMT+1 · GBX
search
Visi simboli
| Simbols | Cena | Izmaiņas | % izmaiņu |
|---|
insights_autoNotiek galveno ieskatu ģenerēšana par šādu tēmu: FARN…
Atvērt
35,06 GBX
Augsta
38,00 GBX
Zema
35,00 GBX
Tirgus kapitalizācija
74,16 milj.
Vid. apjoms
42,63 tūkst.
Apjoms
7,06 tūkst.
Augstākā 52 ned.
193,58 GBX
Zemākā 52 ned.
34,00 GBX
Peļņa uz vienu akciju
-0,10 GBX
Apgrozībā esošās akcijas
31,03 milj.
Darbinieku skaits
36
Atvērt
35,06 GBX
Augsta
38,00 GBX
Zema
35,00 GBX
Tirgus kapitalizācija
74,16 milj.
Vid. apjoms
42,63 tūkst.
Apjoms
7,06 tūkst.
Augstākā 52 ned.
193,58 GBX
Zemākā 52 ned.
34,00 GBX
Peļņa uz vienu akciju
-0,10 GBX
Apgrozībā esošās akcijas
31,03 milj.
Darbinieku skaits
36
Ziņas un raksti
No tīmekļa avotiem un ziņu partneriem
Stocktwits
·
pirms 11 minūtēm
Big Banks Kick Off Q3 Earnings With S&P 500 Near Records — Strategists Flag What Could Move Markets
Cryptonews.net
·
pirms 6 minūtēm
Evernorth Hits Nasdaq With 473 Million XRP as XRPN Trading Begins
www.marketscreener.com
·
pirms 1 stundas
Nextdoor Holdings, Inc. Primary Exchange Listing will Change to Nasdaq Capital Market from New York Stock Exchange
Profils
Faron Pharmaceuticals is a Finnish drug discovery and development company based in Turku, Finland.
The company was founded in 2003 by a group led by Markku Jalkanen, who now acts as the company's Chief Executive Officer. It specialises in the development of treatments for acute organ traumas, vascular damage and cancer immunotherapy.
Its lead product Traumakine has been developed to treat acute respiratory distress syndrome. It is currently undergoing international phase III clinical trials after an open-label, early-phase trial showed promising results in the treatment patients with ARDS. The drug is known to function by enhancing lung CD73 expression and increasing production of anti-inflammatory adenosine, such that vascular leaking and escalation of inflammation are reduced. The U.S. Food and Drug Administration FDA has accepted the proposed protocol design for the next Traumakine study in March 2020. The phase III study is a comparison of efficacy in the treatment of patients with ARDS.
In 2020 Traumakine was selected to take part in the WHO Solidarity trial and REMAP-CAP trials to find drugs for the symptoms of Covid_19. Wikipedia
Par “Faron Pharmaceuticals Oy”
ĢenerāldirektorsMarkku Jalkanen
Darbinieki36
Dibināšanas datums2003
Galvenais birojs-
Sektors-
Tīmekļa vietnefaron.com